EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pirfenidone inhibits TGF‐β1‐induced metabolic reprogramming during epithelial‐mesenchymal transition in non‐small cell lung cancer

Shuling Zhang iD, Yuanmei Wang, Daiqin Luo, Zhimei Cheng, Qibing Zeng, Guoze Wang, Mengxue Chen, Shuai Zhang, Peng Luo

Journal of Cellular and Molecular Medicine · 2024

DOI: 10.1111/jcmm.18059 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2024. Verfasst von Shuling Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Guizhou Medical University, Guiyang, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pyridones. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Daiqin Luo, Peng Luo, Shuling Zhang.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metastasis is an important contributor to increased mortality rates in non‐small cell lung cancer (NSCLC). The TGF‐β signalling pathway plays a crucial role in facilitating tumour metastasis through epithelial‐mesenchymal transition (EMT). Glycolysis, a key metabolic process, is strongly correlated with NSCLC metastasis. Pirfenidone (PFD) has been shown to safely and effectively inhibit TGF‐β1 in patients with lung diseases. Furthermore, TGF‐β1 and glycolysis demonstrate an interdependent relationship within the tumour microenvironment. Our previous study demonstrated that PFD effectively inhibited glycolysis in NSCLC cells, prompting further investigation into its potential antitumour effects in this context. Therefore, the present study aims to investigate the potential antitumour effect of PFD in NSCLC and explore the relationship among TGF‐β1, glycolysis and EMT through further experimentation. The antitumour effects of PFD were evaluated using five different NSCLC cell lines and a xenograft tumour model. Notably, PFD demonstrated a significant antitumour effect specifically in highly glycolytic H1299 cells. To elucidate the underlying mechanism, we compared the efficacy of PFD after pretreatment with either TGF‐β1 or a TGF‐β receptor inhibitor (LY2109761). The energy metabolomics analysis of tumour tissue demonstrated that PFD, a chemosensitizing agent, reduced lactate and ATP production, thereby inhibiting glycolysis and exerting synergistic antineoplastic effects. Additionally, PFD combined with cisplatin targeted TGF‐β1 to inhibit glycolysis during EMT and enhanced the chemosensitization of A549 and H1299 cells. The magnitude of the anticancer effect exhibited by PFD was intricately linked to its metabolic properties.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsPyridonesHumansCell Line, TumorCell MovementEpithelial-Mesenchymal TransitionMetabolic ReprogrammingTransforming Growth Factor beta1Tumor MicroenvironmentAnimals

Stichwörter der Autor:innen

EMTNSCLCTGF-β1glycolysispirfenidone

Substanzen

pirfenidonePyridonesTransforming Growth Factor beta1

Autor:innen und Institutionen

  • Guizhou Medical University, Guiyang, China.
  • Key Laboratory of Environmental Pollution Monitoring and Disease Control, Ministry of Education, School of Public Health, Guiyang, China.
  • State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, China.
  • Guizhou Provincial Engineering Research Center of Food Nutrition and Health, Guizhou Medical University, Guiyang, China.

ORCID-Profile: Shuling Zhang

Förderung

  • Daiqin Luo
  • Peng Luo
  • Shuling Zhang

Zitieren

APA

Zhang, S., Wang, Y., Luo, D., Cheng, Z., Zeng, Q., Wang, G., Chen, M., Zhang, S., & Luo, P. (2024). Pirfenidone inhibits TGF‐β1‐induced metabolic reprogramming during epithelial‐mesenchymal transition in non‐small cell lung cancer. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.18059

Vancouver

Zhang S, Wang Y, Luo D, Cheng Z, Zeng Q, Wang G, et al. Pirfenidone inhibits TGF‐β1‐induced metabolic reprogramming during epithelial‐mesenchymal transition in non‐small cell lung cancer. Journal of Cellular and Molecular Medicine. 2024. doi:10.1111/jcmm.18059

BibTeX
@article{Zhang2024,
  author = {Zhang, Shuling and Wang, Yuanmei and Luo, Daiqin and Cheng, Zhimei and Zeng, Qibing and Wang, Guoze and Chen, Mengxue and Zhang, Shuai and Luo, Peng},
  title = {Pirfenidone inhibits TGF‐β1‐induced metabolic reprogramming during epithelial‐mesenchymal transition in non‐small cell lung cancer},
  journal = {Journal of Cellular and Molecular Medicine},
  year = {2024},
  doi = {10.1111/jcmm.18059}
}
Kostenlos starten →